´ëÇÑÁø´ÜÀ¯ÀüÇÐȸ 2023³â Á¦18Â÷ Çмú´ëȸ (1ÀÏÂ÷) : 2023-06-01
±³À°ÀÏÀÚ : 2023-06-01
±³À°Àå¼Ò : ½ºÀ§½º±×·£µåÈ£ÅÚ ÄÁº¥¼Ç¼¾ÅÍ 4F ÄÁº¥¼ÇȦ
±³À°ÁÖÁ¦ : ´ëÇÑÁø´ÜÀ¯ÀüÇÐȸ 2023³â Á¦18Â÷ Çмú´ëȸ (1ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇÑÁø´Ü°Ë»çÀÇÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Áø´ÜÀ¯ÀüÇÐȸ
´ã´çÀÚ : Á¤¹Ì¼±
¿¬¶ôó : 02-772-9004
À̸ÞÀÏ : ksgd.office@gmail.com
±³À°Á¾·ù : Áø´Ü°Ë»çÀÇÇаú
Âü¼®¿¹»óÀÎ : 250¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 12 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 160,000¿ø
ºñ°í »çÀüµî·Ïºñ : Á¤È¸¿ø 8¸¸¿ø(Àü¹®ÀÇ/±³¼ö/±âŸ) Á¤È¸¿ø 6¸¸¿ø(Àü°øÀÇ/ÀÓ»óº´¸®»ç), Âü°¡È¸¿ø 12¸¸¿ø(Àü¹®ÀÇ), 7¸¸¿ø(Àü°øÀÇ/ÀÓ»óº´¸®»ç/Çлý/¿¬±¸¿ø µî), 15¸¸¿ø(»ê¾÷°è)ÇöÀåµî·Ïºñ: Á¤È¸¿ø 9¸¸¿ø(Àü¹®ÀÇ/±³¼ö) Á¤È¸¿ø 7¸¸¿ø(Àü°øÀÇ/ÀÓ»óº´¸®»ç/Çлý/¿¬±¸¿ø), Âü°¡È¸¿ø 13¸¸¿ø(Àü¹®ÀÇ), 8¸¸¿ø(Àü°øÀÇ/ÀÓ»óº´¸®»ç/Çлý/¿¬±¸¿ø µî), 16¸¸¿ø(»ê¾÷°è)
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06¿ù 01ÀÏ ¼¼¼ÇA(½ºÀ§½º±×·£µåÈ£ÅÚ 4F ÄÁº¥¼ÇAȦ) 09:00~09:30 Assay Validation and Experience with ctDNA Analysis ÀÌÁö¼ö(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06¿ù 01ÀÏ ¼¼¼ÇA(½ºÀ§½º±×·£µåÈ£ÅÚ 4F ÄÁº¥¼ÇAȦ) 09:30~10:00 Current Applications of ctDNA in Precision Oncology ±è¿µ°ï(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 06¿ù 01ÀÏ ¼¼¼ÇA(½ºÀ§½º±×·£µåÈ£ÅÚ 4F ÄÁº¥¼ÇAȦ) 10:00~10:30 The New Era of Liquid Biopsy À̽ÂÅÂ(¿¬¼¼ÀÇ´ë)
Åä·Ð 06¿ù 01ÀÏ ¼¼¼ÇA(½ºÀ§½º±×·£µåÈ£ÅÚ 4F ÄÁº¥¼ÇAȦ) 10:30~10:40 ÁúÀÇÀÀ´ä Q&A ( )
±³À°½Ã°£ 06¿ù 01ÀÏ ¼¼¼ÇA(½ºÀ§½º±×·£µåÈ£ÅÚ 4F ÄÁº¥¼ÇAȦ) 12:00~13:00 Roche Digital Solutions Landscape - Lab & Provider Insights ÃÖÈ«¼º(Çѱ¹·Î½´Áø´Ü)
±³À°½Ã°£ 06¿ù 01ÀÏ ¼¼¼ÇA(½ºÀ§½º±×·£µåÈ£ÅÚ 4F ÄÁº¥¼ÇAȦ) 13:10~13:40 Introduction to Databases and Tools for Multi-Omics Analysis À±Àç¿ø(º¸ÈÆÀÇÇבּ¸¼Ò)
±³À°½Ã°£ 06¿ù 01ÀÏ ¼¼¼ÇA(½ºÀ§½º±×·£µåÈ£ÅÚ 4F ÄÁº¥¼ÇAȦ) 13:40~14:10 Omics Data-Driven Precision Medicine in Cancer ºóÁøÇõ(¿¬¼¼ÀÇ´ë ÀÇ»ý¸í½Ã½ºÅÛÁ¤º¸Çб³½Ç)
±³À°½Ã°£ 06¿ù 01ÀÏ ¼¼¼ÇA(½ºÀ§½º±×·£µåÈ£ÅÚ 4F ÄÁº¥¼ÇAȦ) 14:10~14:40 Introduction to Single Cell and Spatial Analysis using Multi-Omics Platforms ½ÉÁØÈ£(¼º±Õ°üÀÇ´ë ÇǺΰú)
Åä·Ð 06¿ù 01ÀÏ ¼¼¼ÇA(½ºÀ§½º±×·£µåÈ£ÅÚ 4F ÄÁº¥¼ÇAȦ) 14:40~14:50 ÁúÀÇÀÀ´ä Q&A ( )
±³À°½Ã°£ 06¿ù 01ÀÏ ¼¼¼ÇA(½ºÀ§½º±×·£µåÈ£ÅÚ 4F ÄÁº¥¼ÇAȦ) 15:10~15:40 Establishing The Role of Somatic Mutations in Human Brain Diseases ±èÁØÈ£(¼º±Õ°ü´ë »ý¸í°úÇаú)
±³À°½Ã°£ 06¿ù 01ÀÏ ¼¼¼ÇA(½ºÀ§½º±×·£µåÈ£ÅÚ 4F ÄÁº¥¼ÇAȦ) 15:40~16:10 More Accurate ctDNA Analysis for Clinical Application ±è½ÃÇö(¼¿ïÀÇ´ë ÀÓ»óÀ¯ÀüüÀÇÇаú)
±³À°½Ã°£ 06¿ù 01ÀÏ ¼¼¼ÇA(½ºÀ§½º±×·£µåÈ£ÅÚ 4F ÄÁº¥¼ÇAȦ) 16:10~16:40 Detection of Structural Variation in Clinical Sequencing À̼º¿µ(¼¿ïÀÇ´ë ÀÓ»óÀ¯ÀüüÀÇÇаú)
Åä·Ð 06¿ù 01ÀÏ ¼¼¼ÇA(½ºÀ§½º±×·£µåÈ£ÅÚ 4F ÄÁº¥¼ÇAȦ) 16:40~16:50 ÁúÀÇÀÀ´ä Q&A ( )
±³À°½Ã°£ 06¿ù 01ÀÏ ¼¼¼ÇB(½ºÀ§½º±×·£µåÈ£ÅÚ 4F ÄÁº¥¼ÇDEȦ) 09:00~09:30 À¯ÀüÀÚ°Ë»çÆò°¡¿ø ¼÷·ÃµµÆò°¡ ü°è ¹× °³Á¤ »çÇ× ¿ìÈñ¿¬(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 06¿ù 01ÀÏ ¼¼¼ÇB(½ºÀ§½º±×·£µåÈ£ÅÚ 4F ÄÁº¥¼ÇDEȦ) 09:30~09:50 ÇöÀåÆò°¡ °Ë»ç½Ç¿î¿µ ºÐ¾ß ½É»ç Ç׸ñÀÇ ÀÌÇØ ¾ÈÁ¤¿(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 06¿ù 01ÀÏ ¼¼¼ÇB(½ºÀ§½º±×·£µåÈ£ÅÚ 4F ÄÁº¥¼ÇDEȦ) 09:50~10:10 ÇöÀåÆò°¡ ¹üÁÖ 1 ½É»ç Ç׸ñÀÇ ÀÌÇØ °ø¼±¿µ(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 06¿ù 01ÀÏ ¼¼¼ÇB(½ºÀ§½º±×·£µåÈ£ÅÚ 4F ÄÁº¥¼ÇDEȦ) 10:10~10:30 ÇöÀåÆò°¡ ¹üÁÖ 2, 5 ½É»ç Ç׸ñÀÇ ÀÌÇØ ÇѹÎÁ¦(ÇѸ²ÀÇ´ë)
Åä·Ð 06¿ù 01ÀÏ ¼¼¼ÇB(½ºÀ§½º±×·£µåÈ£ÅÚ 4F ÄÁº¥¼ÇDEȦ) 10:30~10:40 ÁúÀÇÀÀ´ä Q&A ( )
±³À°½Ã°£ 06¿ù 01ÀÏ ¼¼¼ÇB(½ºÀ§½º±×·£µåÈ£ÅÚ 4F ÄÁº¥¼ÇDEȦ) 12:00~13:00 Roche Digital Solutions Landscape - Lab & Provider Insights Á¤¿ìÁø(Çѱ¹·Î½´Áø´Ü)
±³À°½Ã°£ 06¿ù 01ÀÏ ¼¼¼ÇB(½ºÀ§½º±×·£µåÈ£ÅÚ 4F ÄÁº¥¼ÇDEȦ) 13:10~13:40 PCR ±â¹Ý °Ë»çÀÇ troubleshooting ±èÁöÀº(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 06¿ù 01ÀÏ ¼¼¼ÇB(½ºÀ§½º±×·£µåÈ£ÅÚ 4F ÄÁº¥¼ÇDEȦ) 13:40~14:10 NGSÀÇ troubleshooting ±èÈƼ®(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 06¿ù 01ÀÏ ¼¼¼ÇB(½ºÀ§½º±×·£µåÈ£ÅÚ 4F ÄÁº¥¼ÇDEȦ) 14:10~14:40 CMAÀÇ troubleshooting ¹ÚÀçÇö(¼¿ïÀÇ´ë)
Åä·Ð 06¿ù 01ÀÏ ¼¼¼ÇB(½ºÀ§½º±×·£µåÈ£ÅÚ 4F ÄÁº¥¼ÇDEȦ) 14:40~14:50 ÁúÀÇÀÀ´ä Q&A ( )
±³À°½Ã°£ 06¿ù 01ÀÏ ¼¼¼ÇB(½ºÀ§½º±×·£µåÈ£ÅÚ 4F ÄÁº¥¼ÇDEȦ) 15:10~15:40 Interpretation Guidelines for Molecular Testing of Cancer: A Review of the AMP/ASCO/CAP and ClinGen/CGC/VICC Standards ±èÇö¿µ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 06¿ù 01ÀÏ ¼¼¼ÇB(½ºÀ§½º±×·£µåÈ£ÅÚ 4F ÄÁº¥¼ÇDEȦ) 15:40~16:10 Challenges of Variant Interpretation of ctDNA in Clinical Laboratory Á¶ÀºÇý(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 06¿ù 01ÀÏ ¼¼¼ÇB(½ºÀ§½º±×·£µåÈ£ÅÚ 4F ÄÁº¥¼ÇDEȦ) 16:10~16:40 Incidental Germline Findings in Cancer Patients Undergoing Molecular Profiling ÀÓÁö¼÷(°í·ÁÀÇ´ë)
Åä·Ð 06¿ù 01ÀÏ ¼¼¼ÇB(½ºÀ§½º±×·£µåÈ£ÅÚ 4F ÄÁº¥¼ÇDEȦ) 16:40~16:50 ÁúÀÇÀÀ´ä Q&A ( )